ArticleOncogene2007
SPARC enhances tumor stroma formation and prevents fibroblast activation.
Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- Omics Overview of the SPARC Gene in Mesothelioma.Biomolecules · 2023Review
- Fibroblasts as Turned Agents in Cancer Progression.Cancers · 2023Review
- Identification of drivers of breast cancer invasion by secretome analysis: insight into CTGF signaling.Scientific reports · 2020Article
- NF1Cancer research · 2017Article
- A holistic approach to dissecting SPARC family protein complexity reveals FSTL-1 as an inhibitor of pancreatic cancer cell growth.Scientific reports · 2016Article
- Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids.Oncotarget · 2016Article
- Stromal fibroblast activation and their potential association with uterine fibroids (Review).Oncology letters · 2014Article
- Personalising pancreas cancer treatment: When tissue is the issue.World journal of gastroenterology · 2014Review
- Recruitment and retention: factors that affect pericyte migration.Cellular and molecular life sciences : CMLS · 2014Review
- Loss of SPARC in bladder cancer enhances carcinogenesis and progression.The Journal of clinical investigation · 2013Article
- Integrin β4 regulates SPARC protein to promote invasion.The Journal of biological chemistry · 2012Article
- Phenformin as prophylaxis and therapy in breast cancer xenografts.British journal of cancer · 2012Article
- The regulatory function of SPARC in vascular biology.Cellular and molecular life sciences : CMLS · 2011Review
- SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity.The Journal of cell biology · 2011Article
- SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer.PloS one · 2011Article
- Article
- Gene signatures in wound tissue as evidenced by molecular profiling in the chick embryo model.BMC genomics · 2010Article
- Cardiac extracellular matrix remodeling: fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC).Journal of molecular and cellular cardiology · 2010Review
- Extracellular matrix proteins and tumor angiogenesis.Journal of oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Tumor growth is influenced by interactions between malignant cells and the tumor stroma. Although the normal host microenvironment is nonpermissive for neoplastic progression, tumor-reactive stroma, characterized by the presence of activated fibroblasts, promotes neoplastic growth and metastasis. Secreted protein, acidic and rich in cysteine (SPARC) is a matricellular glycoprotein that is capable of inhibiting the growth of several different types of cancer. Recently, we reported that SPARC also impairs the growth of xenografts comprised of 293 cells. In this study, we show that in addition to enhancing stroma formation, SPARC prevents fibroblast activation in 293 xenografts, suggesting that the anti-cancer effects of SPARC may be due, at least in part, to the formation of tumor stroma that is not supportive of tumor growth. In vitro, 3T3 fibroblasts cocultured with SPARC-transfected 293 cells remain negative for alpha-smooth muscle actin, whereas wild-type 293 cells induce fibroblast activation. Moreover, activation of 3T3 cells and primary fibroblasts by transforming growth factor beta is blocked by SPARC treatment. We also demonstrate that SPARC significantly increases basic fibroblast growth factor-induced fibroblast migration in vitro, indicating that it may recruit host fibroblasts to the tumor stroma. Taken together, our results suggest that in addition to blocking angiogenesis, SPARC may inhibit tumor growth by promoting the assembly of stroma that is non-permissive for tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.